BaRui Biotech, a subsidiary of Haizheng Pharmaceutical (600267.SH), submitted a listing application to the Hong Kong Stock Exchange

Zhitongcaijing · 5d ago

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. The company learned from its participating subsidiary Zhejiang Borui Biopharmaceutical Co., Ltd. (“vPro Biotech”) that vPro Biotech submitted an initial public offering of overseas listed shares (H shares) to the Hong Kong Stock Exchange on January 6, 2026 and listed the application materials for this offering on the Hong Kong Stock Exchange website on the same day.

vRui Biotech is a leading domestic biopharmaceutical company focusing on immunotherapy, and has comprehensive R&D, production and marketing capabilities. Since its establishment, vRui Biotech has been committed to providing comprehensive immunotherapy solutions for patients with autoimmune diseases, inflammatory diseases, tumor immune diseases, and malignant tumor diseases caused by immune system disorders. As of the disclosure date, the company held 39.62% of vPro Biotech's shares.